Literature DB >> 23634944

Telomere-homologous G-rich oligonucleotides sensitize human ovarian cancer cells to TRAIL-induced growth inhibition and apoptosis.

Sibaji Sarkar1, Douglas V Faller.   

Abstract

G-rich T-oligos (GT-oligos; oligonucleotides with homology to telomeres) elicit a DNA damage response in cells and induce cytotoxic effects in certain tumor cell lines. We have previously shown that GT-oligo inhibits growth, arrests cell cycle, and induces apoptosis in ovarian, pancreatic, and prostate cancer cells. However, not all ovarian cancer cell lines are susceptible to GT-oligo exposure. GT-oligo was found to induce transcript expression of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors DR-4 and DR-5, which are generally silenced in ovarian cancer cells, rendering them insensitive to TRAIL. Exposure of TRAIL- and GT-oligo-resistant cell lines to GT-oligo rendered them sensitive to the cytotoxic effects of TRAIL, producing more than additive inhibition of growth. An intracellular inhibitor of the extrinsic apoptotic pathway, FLICE-like Inhibitory Protein-Short (FLIPs), was down-regulated and Jun kinase (JNK) was activated by exposure to GT-oligo. JNK inhibition partially reversed the growth inhibition caused by the combination of GT-oligo and TRAIL indicating partial involvement of the Jun kinase pathway in the resulting cytotoxic effect. Both capase-8 and caspases 3/7 were activated by exposure to GT-oligo plus TRAIL, consistent with activation of the extrinsic apoptotic pathway. These results demonstrate a novel way of sensitizing resistant ovarian cancer cells to TRAIL-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23634944      PMCID: PMC3660071          DOI: 10.1089/nat.2012.0401

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  24 in total

1.  Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.

Authors:  Sandra Tomek; Peter Horak; Ingrid Pribill; Griet Haller; Max Rössler; Christoph C Zielinski; Dietmar Pils; Michael Krainer
Journal:  Gynecol Oncol       Date:  2004-07       Impact factor: 5.482

2.  Identification and characterization of a new member of the TNF family that induces apoptosis.

Authors:  S R Wiley; K Schooley; P J Smolak; W S Din; C P Huang; J K Nicholl; G R Sutherland; T D Smith; C Rauch; C A Smith
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

Review 3.  Death and anti-death: tumour resistance to apoptosis.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

4.  Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.

Authors:  R M Pitti; S A Marsters; S Ruppert; C J Donahue; A Moore; A Ashkenazi
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

5.  Mechanism of T-oligo-induced cell cycle arrest in Mia-PaCa pancreatic cancer cells.

Authors:  Andrew M Rankin; Sibaji Sarkar; Douglas V Faller
Journal:  J Cell Physiol       Date:  2012-06       Impact factor: 6.384

6.  Telomere-based DNA damage responses: a new approach to melanoma.

Authors:  Neelu Puri; Mark S Eller; H Randolph Byers; Sarah Dykstra; John Kubera; Barbara A Gilchrest
Journal:  FASEB J       Date:  2004-09       Impact factor: 5.191

7.  Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.

Authors:  M Chawla-Sarkar; S I Bae; F J Reu; B S Jacobs; D J Lindner; E C Borden
Journal:  Cell Death Differ       Date:  2004-08       Impact factor: 15.828

8.  Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP.

Authors:  Ville Hietakangas; Minna Poukkula; Kaisa M Heiskanen; Jarkko T Karvinen; Lea Sistonen; John E Eriksson
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

9.  Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice.

Authors:  E Zhao; M Zhou; C Fu; B Shen; Q Zhang; L Lian
Journal:  Chin Med J (Engl)       Date:  1995-08       Impact factor: 2.628

10.  X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells.

Authors:  Jordan M Cummins; Manu Kohli; Carlo Rago; Kenneth W Kinzler; Bert Vogelstein; Fred Bunz
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

View more
  9 in total

1.  Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides.

Authors:  Neelu Puri; Ryan T Pitman; Richard E Mulnix; Terrianne Erickson; Audra N Iness; Connie Vitali; Yutong Zhao; Ravi Salgia
Journal:  Cancer Lett       Date:  2013-09-14       Impact factor: 8.679

2.  Telomere Fragment Induced Amnion Cell Senescence: A Contributor to Parturition?

Authors:  Jossimara Polettini; Faranak Behnia; Brandie D Taylor; George R Saade; Robert N Taylor; Ramkumar Menon
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

Review 3.  Cancer development, progression, and therapy: an epigenetic overview.

Authors:  Sibaji Sarkar; Garrick Horn; Kimberly Moulton; Anuja Oza; Shannon Byler; Shannon Kokolus; McKenna Longacre
Journal:  Int J Mol Sci       Date:  2013-10-21       Impact factor: 5.923

Review 4.  Treating Cancer by Targeting Telomeres and Telomerase.

Authors:  Marko Ivancich; Zachary Schrank; Luke Wojdyla; Brandon Leviskas; Adijan Kuckovic; Ankita Sanjali; Neelu Puri
Journal:  Antioxidants (Basel)       Date:  2017-02-19

Review 5.  Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity.

Authors:  Ganiou Assani; Yudi Xiong; Fuxiang Zhou; Yunfeng Zhou
Journal:  Oncotarget       Date:  2018-10-09

Review 6.  Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy.

Authors:  Meghan Leary; Sarah Heerboth; Karolina Lapinska; Sibaji Sarkar
Journal:  Cancers (Basel)       Date:  2018-12-04       Impact factor: 6.639

Review 7.  Drug resistance in cancer: an overview.

Authors:  Genevieve Housman; Shannon Byler; Sarah Heerboth; Karolina Lapinska; Mckenna Longacre; Nicole Snyder; Sibaji Sarkar
Journal:  Cancers (Basel)       Date:  2014-09-05       Impact factor: 6.639

8.  Cytotoxicity of guanine-based degradation products contributes to the antiproliferative activity of guanine-rich oligonucleotides.

Authors:  Nan Zhang; Tao Bing; Xiangjun Liu; Cui Qi; Luyao Shen; Linlin Wang; Dihua Shangguan
Journal:  Chem Sci       Date:  2015-04-07       Impact factor: 9.825

Review 9.  Oligonucleotides Targeting Telomeres and Telomerase in Cancer.

Authors:  Zachary Schrank; Nabiha Khan; Chike Osude; Sanjana Singh; Rachel J Miller; Collin Merrick; Alexander Mabel; Adijan Kuckovic; Neelu Puri
Journal:  Molecules       Date:  2018-09-05       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.